Treatment of cancer using anti-TGF-BETA and PD-1 antibodies

1. A method for treating cancer or reducing the recurrence of cancer comprising administering to a subject having cancer or who has had cancer, in therapeutically effective amounts, an inhibitor of transforming growth factor beta (TGFβ) and an inhibitor of Programmed cell death protein 1 (PD-1), wherein the PD-1 inhibitor is an anti-PD-1 antibody; and

wherein the TGFβ inhibitor is an antibody that binds TGFβ comprising:

a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NO: 19;

b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NO: 20;

c) a heavy chain CDR3 amino acid sequence set forth in SEQ ID NO: 21;

d) a light chain CDR1 amino acid sequence set forth in SEQ ID NO: 22;

e) a light chain CDR2 amino acid sequence set forth in SEQ ID NO: 23; and

f) a light chain CDR3 amino acid sequence set forth in SEQ ID NO: 24.

2. The method of claim 1 , wherein the antibody binds TGFβ1, TGFβ2 and TGFβ3.

3. The method of claim 1 , wherein the antibody binds to TGFβ1 and TGFβ2 with greater affinity than to TGFβ3.

4. The method of claim 2 , wherein the TGFβ antibody binds to TGFβ1, TGFβ2 and TGFβ3 with an affinity Kd from 10-6 M to 10-12 M.

5. The method of claim 1 wherein the TGFβ inhibitor is an antibody that comprises an amino acid sequence at least 95% identical to a heavy chain variable region amino acid sequence set forth in SEQ ID NO: 6 and comprises HCDR1, HCDR2 and HCDR3 amino acid sequences set out in SEQ ID NO: 19-21.

6. The method of claim 5 wherein the antibody further comprises an amino acid sequence at least 95% identical to a light chain variable region amino acid sequence set forth in SEQ ID NO: 8 and comprises LCDR1, LCDR2 and LCDR3 amino acid sequences set out in SEQ ID NO: 22-24.

7. The method of claim 4 wherein

the heavy chain variable region amino acid sequence is set forth in SEQ ID NO: 6 and the light chain variable region amino acid sequence is set forth in SEQ ID NO: 8.

8. The method of claim 1 wherein the TGFβ antibody further comprises a heavy chain constant region, wherein the heavy chain constant region is a modified or unmodified IgG, IgM, IgA, IgD, IgE, a fragment thereof, or combinations thereof.

9. The method of claim 8 further comprising a human light chain constant region attached to said light chain variable region.

10. The method of claim 1 , wherein the cancer is selected from the group consisting of esophageal cancer, pancreatic cancer, metastatic pancreatic cancer, metastatic adenocarcinoma of the pancreas, bladder cancer, stomach cancer, fibrotic cancer, glioma, malignant glioma, diffuse intrinsic pontine glioma, recurrent childhood brain neoplasm renal cell carcinoma, clear-cell metastatic renal cell carcinoma, kidney cancer, prostate cancer, metastatic castration resistant prostate cancer, stage IV prostate cancer, metastatic melanoma, melanoma, malignant melanoma, recurrent melanoma of the skin, melanoma brain metastases, stage IIIA skin melanoma; stage IIIB skin melanoma, stage IIIC skin melanoma; stage IV skin melanoma, malignant melanoma of head and neck, lung cancer, non small cell lung cancer (NSCLC), squamous cell non-small cell lung cancer, breast cancer, recurrent metastatic breast cancer, hepatocellular carcinoma, hodgkin's lymphoma, follicular lymphoma, non-hodgkin's lymphoma (NHL), advanced B-cell NHL, HL including diffuse large B-cell lymphoma (DLBCL), multiple myeloma, chronic myeloid leukemia, adult acute myeloid leukemia in remission; adult acute myeloid leukemia with Inv(16)(p13.1q22); CBFB-MYH11; adult acute myeloid leukemia with t(16;16)(p13.1;q22); CBFB-MYH11; adult acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1; adult acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL; adult acute promyelocytic leukemia with t(15;17)(q22;q12); PML-RARA; alkylating agent-related acute myeloid leukemia, chronic lymphocytic leukemia, richter's syndrome; waldenstrom macroglobulinemia, adult glioblastoma; adult gliosarcoma, recurrent glioblastoma, recurrent childhood rhabdomyosarcoma, recurrent ewing sarcoma/peripheral primitive neuroectodermal tumor, recurrent neuroblastoma; recurrent osteosarcoma, colorectal cancer, MSI positive colorectal cancer; MSI negative colorectal cancer, nasopharyngeal nonkeratinizing carcinoma; recurrent nasopharyngeal undifferentiated carcinoma, cervical adenocarcinoma; cervical adenosquamous carcinoma; cervical squamous cell carcinoma; recurrent cervical carcinoma; stage IVA cervical cancer; stage IVB cervical cancer, anal canal squamous cell carcinoma; metastatic anal canal carcinoma; recurrent anal canal carcinoma, recurrent head and neck cancer; carcinoma, squamous cell of head and neck, head and neck squamous cell carcinoma (HNSCC), ovarian carcinoma, colon cancer, gastric cancer, advanced GI cancer, gastric adenocarcinoma; gastroesophageal junction adenocarcinoma, bone neoplasms, soft tissue sarcoma; bone sarcoma, thymic carcinoma, urothelial carcinoma, recurrent merkel cell carcinoma; stage III merkel cell carcinoma; stage IV merkel cell carcinoma, myelodysplastic syndrome and recurrent mycosis fungoides and Sezary syndrome.

11. The method of claim 1 wherein the cancer is selected from the group consisting of non small cell lung carcinoma (NSCLC), head and neck cancer, skin cancer, melanoma and squamous cell carcinoma (SCC).

12. The method of claim 1 comprising reducing tumor size or tumor burden in the subject, optionally wherein the tumor size is reduced by 20% or more, or reducing metastasis in the subject.

13. The method of claim 1 wherein the PD-1 inhibitor and the TGFβ inhibitor are formulated in a pharmaceutical composition.

14. The method of claim 1 wherein the administration reduces the recurrence of cancer in a subject that has received inhibitor therapy.

15. The method of claim 1 wherein the TGFβ inhibitor is administered in a dose range of 0.1 to 15 mg/kg and the PD-1 inhibitor is administered in a dose range from 0.1 to 15 mg/kg.